BioAtla, Inc. — Director's Dealing 2022

Jun 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioAtla, Inc. (BCAB)
CIK: 0001826892
Period of Report: 2022-06-16

Reporting Person: MCBRINN SYLVIA (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-16	Stock Option (right to buy)	$2.48	A	20000	Acquired	2032-06-16	Common Stock (20000)	Direct
2022-06-16	Stock Option (right to buy)	$39.64	A	5695	Acquired	2031-06-15	Common Stock (5695)	Direct

Footnotes

F1: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date.

F2: On June 17, 2021, the reporting person filed a Form 4 in respect of an option covering 24,615 shares. Such option was granted on June 15, 2021 pursuant to the Company's non-employee director compensation policy. The Company subsequently determined that 5,695 of the shares comprising such award were null and void upon grant as a result of the $750,000 annual limit for non-employee director compensation under its 2020 Equity Incentive Plan. As a result on June 16, 2022, the Board of the Company granted a make-whole option covering 5,695 shares to the reporting person. Such make-whole option has the same vesting, expiration and other terms as the option granted on June 15, 2021.

F3: 1/3 of the total number of shares subject to the make-whole option were fully vested and exercisable on the date of the grant and 1/36th of the total number of shares subject to the make-whole option shall vest monthly commencing on July 15, 2022, subject to the reporting person continuing to provide services to the Company throughout the vesting date.